Effect of Dexmedetomidine As Adjuvant to Ropivacaine for Brachial Plexus Block

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05767827

Enrollment

Registered

2023-03-14

Start date

2023-02-01

Completion date

2024-08-30

Last updated

2024-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brachial Plexus Block, Local Anesthesia Adjuvants, Upper Extremity Fracture

Brief summary

Brachial plexus block is used for upper limb surgery. Local anesthesia alone for brachial plexus block provides good operative conditions, but have short duration of postoperative analgesia. Hence, various adjuvants to local anaesthetic agents to prolong the duration of peripheral nerve, analgesia. However, results are either inconclusive or associated with side effects. The purpose of this study is to determine whether dexmedetomidine as an adjuvant to ropivacaine in brachial plexus block improve quality of block in terms of duration of post operative analgesia.

Interventions

DRUGropivacaine, lidocaine with adrenaline

Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml

DRUGDexmedetomidine, ropivacaine, lidocaine with adrenaline

Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

* ASA physical status I and II patients, weight 45 to 74 kg * Elective upper limb surgery under brachial plexus block

Exclusion criteria

* known hypersensitivity or contraindication to ropivacaine, lidocaine and dexmedetomidine * Pregnant or lactating mothers * Hepatic, renal or cardiopulmonary abnormalities * Long term analgesic therapy

Design outcomes

Primary

Measure	Time frame	Description
Assess the duration of analgesia after brachial plexus block with ropivacaine and dexmedetomidine	5 months	Analgesia will be assessed with the help of Visual analogue score ( VAS). VAS greater than 3 will be given inj.ketorolac 30mg IV.
Assess the onset of sensory and motor block after brachial plexus block with ropivacaine and dexmedetomidine	5 months	Sensory block assessed by 3point scale 0 normal sensation 1. loss of sensation of pinprick 2. loss of sensation of touch Duration of sensory block, defined as time interval between complete sensory block and complete resolution of anesthesia (score 0).Motor blockade assessed by modified Bromage scale (MBS) 0-able to raise extended arm to 90 degree for full two seconds 1. able to flex elbow, move fingers but unable to raise extended arm 2. unable to flex elbow but able to move fingers 3. unable to move arm, elbow, fingers Duration of motor block defined as time interval from complete motor block to recovery of complete motor function (MBS 0).
Assess the duration of sensory and motor block after brachial plexus block with ropivacaine and dexmedetomidine	5months	Duration of sensory block, defined as time interval between complete sensory block and complete resolution of anesthesia (score 0). Duration of motor block defined as time interval from complete motor block to recovery of complete motor function (MBS 0).

Secondary

Measure	Time frame	Description
Assess any complications of study drugs	5 months	Complications like bradycardia assessed by continue ECG monitoring, Hypotension will be assessed by NIBP

Countries

Nepal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026